-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a domestic multi-center team published a study in the journal Frontiers in Oncology, mainly to evaluate the efficacy of Regorafenib (regorafenib) third-line or above in the treatment of patients with refractory metastatic colorectal cancer (mCRC)
The study included patients with refractory metastatic colorectal cancer (mCRC) from 4 centers in China between February 1, 2018 and June 31, 2021, divided into 3 groups: regorafenib monotherapy, regorafenib Combined chemotherapy group and regorafenib combined with anti-PD-1 treatment group
A total of 177 patients were included in this study, of which 116 (65.
The median follow-up time was 9.
The median follow-up time was 9.
Median PFS was longer in the regorafenib plus immunization group than in the monotherapy group (3.
Median PFS was longer in the regorafenib plus immunization group than in the monotherapy group (3.
Patients who started treatment at 120 mg had longer PFS and OS compared to those who started treatment at 80 mg (PFS: mPFS: 3.
Patients who started treatment at 120 mg had longer PFS and OS compared to those who started treatment at 80 mg (PFS: mPFS: 3.
All 177 patients were assessed for toxicity
In conclusion, the study showed that in patients with refractory mCRC, regorafenib combined with immunotherapy had better PFS, while combined with chemotherapy had better OS
Studies have shown that in patients with refractory mCRC, regorafenib combined with immunotherapy has better PFS and better OS when combined with chemotherapy
Xu D, Liu Y, Tang W, Xu L, Liu T, Jiang Y, Zhou S, Qin X, Li J, Zhao J, Ye L, Chang W and Xu J (2022) Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi -Center Retrospective Study.
Xu D, Liu Y, Tang W, Xu L, Liu T, Jiang Y, Zhou S, Qin X, Li J, Zhao J, Ye L, Chang W and Xu J (2022) Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi -Center Retrospective Study.
Front.
Oncol.
12:838870.
doi: 10.
3389/fonc.
2022.
838870Leave
a message here